Valuate Health Consultancy: 2021


Valuate Health Consultancy

290 Congress Street

Boston, MA 02210





Account wins 27

Active business clients 23

Brands by 2020 sales

Brand-product accounts held 39



Market access consulting 100%



Abbott Diagnostics

Academy of Managed Care Pharmacy



Boehringer Ingelheim

Bristol Myers Squibb







Intra-Cellular Therapies





Otsuka America Pharmaceutical







Valuate Health Consultancy launched in 2019 as the market access consultancy offering of Omnicom Health Group (OHG). “We specialize in optimizing market access and value strategy for drug, device, and diagnostics manufacturers and collaborate with our clients to solve complex access and reimbursement challenges via data-driven, agile, and innovative solutions,” management says. The Valuate team is composed of former market access executives, pharmacists, data scientists, and business strategists working together to take a strategic approach to access and reimbursement challenges in an evolving industry.

Valuate leverages an extensive network of more than 600 market access KOLs across the country, innovative research methods, and industry-leading data analytics, according to the leadership team. “We offer an array of services to our clients to evaluate reimbursement potential for assets, design and translate health economics evidence, develop and validate product value platforms, respond to health policy changes, understand and support organizational customers, develop pricing and contracting approaches, and formulate strategies to ensure products can break through market access barriers and effectively reach patients.” 

(left to right) Dina Steinfurth, managing director; Caleb DesRosiers, senior principal; Tony Gibson, principal; Lori Wood, principal; Susan Weber, principal; John Hennessy, principal; Jack Timko, principal


According to management, fueling Valuate’s tremendous accolades is an unwavering commitment to client success.  

During 2020, Valuate continued to develop a breadth of proprietary tools to meet clients’ diverse needs. Among these tools are Entrée Health Engagement Engine, a proven approach that aggregates data for customers in a fully interoperable manner. “Our proprietary backend platform feeds a customizable framework, tailored to each client’s needs. The Engagement Engine powers multiple offerings, including CognuityTM, a data-driven, self-learning platform designed to enable intelligent interactions, as well as a robust pullthrough platform.” 

Other tools are ECOsystemTM, an integrated analysis to optimize communications and build customer equity through segmentation, influencer mapping, and archetyping; Evidence AuditTM and Trends Reporting, a deep analysis of baseline evidence and trends through publication database research, economic literature, and news and social media outlets to optimize value stories to fill key data gaps and find methodologies that meet customer business priorities; and MARCOTM Rapid-response Payer Insights, a survey platform to reach access customers directly for real-time access insights. “We often add in-depth interviews with our value influencers to dive deeper into complex access research hypothesis,” management says.

In addition to expanding product offerings and proprietary tools, Valuate has added 18 clients to its roster. “Our team has also grown from a handful of employees to 19 experts who bring broad market access experience spanning payer strategy and health system expertise, industry and government affairs, data science, content strategy, and operational excellence to client engagements,” according to Valuate leaders.

Members of the Valuate leadership team serve as board members at organizations including the Henry Ford Health System, Health Alliance Plan (HAP), Young Survival Coalition and the Academy of Managed Care Pharmacy (AMCP).


In 2021 Valuate is expanding its capabilities in growing areas where access matters, according to the leadership team. 

“We’re focusing on developing large-scale value based partnerships to help smaller pharma and biotech companies partner with large health systems to drive precision medicine and enhance population-based care,” Valuate executives say. “We’re helping clients prepare for healthcare technology assessments to ensure innovative devices and diagnostics are available and accessible to patients quickly. We’re partnering with cutting-edge, venture-backed technology companies to integrate and streamline administrative processes that often act as barriers to access. We’re implementing new solutions at the enterprise level and moving toward portfolio-level solutions to extend the reach of our client collaborations.”


Along with the team’s immersion in client initiatives, Valuate is actively engaged in OHG’s model of giving back. Valuate is working with the Young Survival Coalition to give voice to the unique needs of young women with breast cancer. 

Valuate is partnered with the OHG Diversity, Equity, and Inclusion department to inspire clients to invest in improving social determinants of health and address inequities in healthcare access related to their products and/or devices. 

“Our team will continue to put our mission at the forefront of our work, striving to find opportunities to help patient communities get access to the healthcare they need,” according to Valuate management. “In bringing new questions and comprehensive, solution-focused thinking to the table, the Valuate team is committed to reshaping what access, reimbursement and affordability can mean for all audiences.”